Sets a new benchmark in affordability for GLP-1 therapy, with weekly treatment starting at ₹325
Bangalore, March 22: Glenmark Pharmaceuticals Ltd., a research-led global pharmaceutical company, has announced the launch of GLIPIQⓇ (semaglutide) in India for the management of Type 2 Diabetes Mellitus (T2DM). The launch sets a new benchmark in affordability for GLP-1 therapy, significantly expanding access to advanced diabetes treatment for patients across the country.
GLIPIQⓇ has been approved by the Central Drugs Standard Control Organization (CDSCO) following a multicentre, randomised, comparative, active-controlled, open-label Phase III clinical study conducted in India, which demonstrated favourable efficacy and safety outcomes in patients with Type 2 diabetes.
The therapy is available in both vial and pre-filled pen formats. The expected weekly treatment cost using vials ranges from ₹325 to ₹440, substantially lowering the cost barrier for initiating GLP-1 therapy in India. The pre-filled pen offers the added convenience of self-administration for long-term use, enabling patients to manage their condition more independently.
Together, the vial and pen formats support a structured and flexible treatment pathway—facilitating smoother therapy initiation, improved adherence, and sustained clinical outcomes. Both formats are available in strengths of 2 mg/1.5 mL, 4 mg/3 mL, and 8 mg/3 mL.
To further support patients, Glenmark has introduced ‘Sankalp’, a patient support programme (PSP) aimed at assisting therapy initiation, improving comfort with injectable treatments, and encouraging long-term adherence. The initiative underscores the company’s commitment not only to affordability but also to enabling better health outcomes through sustained treatment.
Commenting on the launch, Alok Malik, President and Business Head – India Formulations, Glenmark Pharmaceuticals Ltd., said, “Affordability remains one of the biggest barriers to initiating advanced diabetes therapies in India. With GLIPIQⓇ, we are setting a new benchmark in accessibility for GLP-1 therapy, with weekly treatment starting at ₹325. The vial-based format allows us to offer a more affordable option while supporting clinically guided initiation and flexible dosing. Building on our experience in the GLP-1 category, including Lirafit™ (liraglutide), and supported by our ‘Sankalp’ programme, we aim to help more patients access, initiate, and continue therapy over time.”
